We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Genome Sciences Expands its Scientific Advisory Board
News

Oxford Genome Sciences Expands its Scientific Advisory Board

Oxford Genome Sciences Expands its Scientific Advisory Board
News

Oxford Genome Sciences Expands its Scientific Advisory Board

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Genome Sciences Expands its Scientific Advisory Board"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Genome Sciences (UK) Ltd “OGeS” has announced that it has further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr Mike Gresser.

Dr Gresser, who is currently Visiting Scholar at the Molecular Biology Institute at UCLA, has significant pharmaceutical and academic experience which compliments the skills of the other members of the OGeS’ SAB.

Prior to taking up his current position, Dr Gresser worked at Amgen Inc., Thousand Oaks, CA, USA, where he was for six years Vice President Research for Inflammation and for two years he also held the position of Head of Neuroscience Research.

At Amgen, he worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development.

Before joining Amgen, Dr Gresser worked for 12 years at the Merck Frost Center for Therapeutic Research in Kirkland, Quebec where his final position was Executive Director of Biochemistry and Molecular Biology. While at Merck, Mike and his team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials, including Singulair and Vioxx.

Dr Gresser received his Ph.D. in Biochemistry in 1976 from Brandeis University, where his thesis research was done under the supervision of W.P. Jencks on the mechanism of ester aminolysis.  He did postdoctoral studies at the Molecular Biology Institute at UCLA on the mitochondrial and chloroplast proton translocating adenosine triphosphate (ATP) synthases. He carried out this work under the supervision of Paul D. Boyer, who won the Nobel Prize in Chemistry in 1997 for his part in the elucidation of the enzymatic mechanism underlying the synthesis of ATP.

Dr Mike Gresser commented: “I have been highly impressed with the progress that Oxford Genome Sciences has made in such a short time. I have little doubt that Christian and his team backed by the unique resources of the OGAP database will be able to play a major role in developing the personalised medicines that are clearly required to improve the treatment of major diseases such as cancer and Alzheimer’s disease.”

“I look forward to contributing to OGeS’s exciting future and to working with my colleagues on the company’s high quality SAB,” he continued.

Advertisement